Company intelligence / Profile preview

Denali Ventures

South San Francisco, California, United States

Ownership: Private
Employees: ~517
Development stage: Other

Overview

Tividenofusp alfa (DNL310) received FDA Breakthrough Therapy Designation in Jan 2025 and BLA accepted for Priority Review in Jul 2025 for Hunter syndrome (MPS II), with PDUFA target early 2026. Other programs in Phase 1/2 and preclinical stages.

Therapeutic areas: NeurologyRare Diseases
Modalities: Enzyme replacement therapySmall moleculeMonoclonal antibody
Industry: Biotech

Partnerships

BiogenTakedaSanofiRoyalty Pharma

Beyond the preview

Go deeper on Denali Ventures.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Denali Ventures.

Explore the full profile